Carbon 14 synthesis of glycine transporter 1 inhibitor Iclepertin (BI 425809) and its major metabolites

Carbon 14 labeled Iclepertin (BI 425809, 1) and its major metabolites were needed for ADME and several other studies necessary for the advancement of this drug candidate in clinical trials. Iclepertin is composed of two main chemical blocks, (R)-5-(methylsulfonyl)-2-([1,1,1-trifluoropropan-2-yl]oxy)...

Full description

Saved in:
Bibliographic Details
Published in:Journal of labelled compounds & radiopharmaceuticals 2023-09, Vol.66 (11), p.336-344
Main Authors: Latli, Bachir, Hrapchak, Matt J, Frutos, Rogelio P, Lee, Heewon, Song, Jinhua J
Format: Article
Language:English
Subjects:
Benzoic acid
Carbon
Carbon 14
Clinical trials
Drug development
Glycine
Glycine transporter
Intermediates
Metabolites
Radiochemistry
Synthesis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Carbon 14 labeled Iclepertin (BI 425809, 1) and its major metabolites were needed for ADME and several other studies necessary for the advancement of this drug candidate in clinical trials. Iclepertin is composed of two main chemical blocks, (R)-5-(methylsulfonyl)-2-([1,1,1-trifluoropropan-2-yl]oxy)benzoic acid (2), and 3-[(1R,5R)-3-azabicyclo[3.1.0]hexan-5-yl]-5-(trifluoromethyl)isoxazole (3) linked to each other via an amide bond. In the first synthesis of carbon 14 labeled 1, 2-fluorobenzoic acid, carboxyl- C was converted to [ C]-2 in three steps and then coupled to 3 to provide [ C]-1a in 45% overall yield. In the second synthesis, [ C]-3 was prepared in six radioactive steps and coupled to the acid 2 to furnish [ C]-1b in 20% overall yield. Both synthetic routes provided [ C]-1a and [ C]-1b with specific activities higher than 53 mCi/mmol and radiochemical, chemical, and enantiomeric purities above 98%. Two major metabolites of 1, BI 761036 and BI 758790, were also prepared labeled with carbon 14 using intermediates already available from the synthesis of [ C]-1.
ISSN:0362-4803
1099-1344
DOI:10.1002/jlcr.4051